Study shows Favipiravir gives various advantages in COVID-19 treatment: Glenmark Pharmaceuticals

Study shows Favipiravir gives various advantages in COVID-19 treatment: Glenmark Pharmaceuticals


  • Post By : Kumar Jeetendra

  • Source: PTI

  • Date: 23 Nov,2020

Drug firm Glenmark Pharmaceuticals on Monday said according to a recently released data the oral antifungal medication Favipiravir was found to provide multiple benefits in COVID-19 treatment including faster time to clinical cure.

These findings have been observed in a randomised, controlled Phase 3 clinical study conducted by the organization and the results have been published online in the International Journal of Infectious Diseases (IJID), Glenmark said in a regulatory filing.

The Phase 3 study with Favipiravir, sold under the brand name FabiFlu, from the company was conducted in 150 patients, it included.

Favipiravir was found to provide multiple treatment benefits, demonstrated by quicker time to clinical treatment, and significantly delayed the need for supportive oxygen therapy, Glenmark stated.

“Additionally, patients of confirmed COVID-19 with moderate symptoms were discharged from hospital sooner than those patients that did not get Favipiravir, with the median time to clinical treatment decreased by 2.5 days compared with the control group,” it added.

Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby stopping the virus’s replication cycle. This helps control the multiplication of the virus and prevents its spread in the individual, Glenmark stated.

“It is encouraging to see our trial results now published in a trusted global medical journal, which we expect will support other countries in their struggle against this disease,” Glenmark Pharmaceuticals Chief Commercial Officer Robert Crockart stated.

In June 2020, the firm had received manufacturing and marketing approval from India’s drug regulator for its generic version of Favipiravir, for the treatment of mild to moderate COVID-19, Glenmark stated.

Shares of Glenmark Pharmaceuticals were trading at Rs 485.30 per scrip on BSE, up 0.80 percent from its previous close.

About Author